FDA approves Stiefel acne treatment

Fabior approved for patients ages 12 years and older

NEW YORK — The Food and Drug Administration has approved a new treatment for acne made by a GlaxoSmithKline subsidiary.

Stiefel announced the approval of Fabior (tazarotene) foam in the 0.1% strength, calling it the only retinoid in a topical foam for treating acne in patients ages 12 years and older.

"Stiefel is dedicated to meeting th needs of patients and dermatologists, and we believe Fabior foam will be an important treatment option for people with moderate-to-severe acne," Stiefel VP North America dermatology Jean-Christophe May said.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

Login or Register to post a comment.